SAC Capital indicted in 6-year US insider trading probe
SAC was indicted on 4 counts of securities fraud, 1 count of wire fraud in an indictment unsealed in Manhattan federal court
Premium(Reuters)
Manhattan: SAC Capital Advisors LP, the $14 billion hedge fund founded by Steven A. Cohen, was indicted by a US grand jury as part of the government’s six-year crackdown on insider trading on Wall Street.
The charges against the Stamford, Connecticut-based hedge fund are the most significant to be brought by the US since former Goldman Sachs Group Inc. director Rajat Gupta was accused of insider trading in October 2011. Gupta, convicted in New York federal court last year, was sentenced to two years in prison.
This isn’t the first time Manhattan US attorney Preet Bharara has sought charges against a business. In February 2012, his office charged Wegelin & Co., Switzerland’s oldest private bank, for helping US taxpayers hide assets from the Internal Revenue Service. Wegelin pleaded guilty and was ordered to pay almost $58 million.
SAC was indicted on four counts of securities fraud and one count of wire fraud in an indictment unsealed in Manhattan federal court. The US securities and exchange commission, in an administrative action on 19 July, accused Cohen of failing to supervise two portfolio managers who both face insider trading charges. Cohen wasn’t charged in today’s indictment.
While the agency stopped short of accusing Cohen of insider trading himself, the SEC alleged he received highly suspicious information and ignored red flags that should have caused any reasonable hedge-fund manager to investigate the basis for trades made by SAC employees Mathew Martoma and Michael Steinberg. Those trades helped the hedge fund earn profits and avoided losses of more than $275 million in 2008, the SEC said.
Charged
Martoma, 39, was charged in November by Bharara with the most lucrative insider trading case in history. Prosecutors said Martoma helped SAC reap hundreds of millions in illegal profits on tips provided by a doctor about a clinical trial about an Alzheimer’s drug being developed by Wyeth LLC and Elan Corp.
Martoma, who has pleaded not guilty, is scheduled to go to trial in Manhattan federal court on 4 November.
While Cohen wasn’t charged with Martoma, that case was the first to link Cohen directly to alleged inside information. BLOOMBERG
"Exciting news! Mint is now on WhatsApp Channels 🚀 Subscribe today by clicking the link and stay updated with the latest financial insights!" Click here!
